NJ State Employees Deferred Compensation Plan’s Vertex Pharmaceuticals VRTX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$392K	–	401
2025 Q3	$392K	Hold	1,000	–	–	0.04%	319
2025 Q2	$445K	Hold	1,000	–	–	0.05%	296
2025 Q1	$485K	Hold	1,000	–	–	0.06%	275
2024 Q4	$403K	Hold	1,000	–	–	0.05%	328
2024 Q3	$465K	Hold	1,000	–	–	0.06%	306
2024 Q2	$469K	Hold	1,000	–	–	0.06%	294
2024 Q1	$418K	Hold	1,000	–	–	0.05%	321
2023 Q4	$407K	Hold	1,000	–	–	0.06%	326
2023 Q3	$348K	Hold	1,000	–	–	0.05%	333
2023 Q2	$352K	Hold	1,000	–	–	0.05%	341
2023 Q1	$315K	Hold	1,000	–	–	0.05%	367
2022 Q4	$289K	Hold	1,000	–	–	0.05%	367
2022 Q3	$290K	Hold	1,000	–	–	0.05%	362
2022 Q2	$282K	Hold	1,000	–	–	0.05%	370
2022 Q1	$261K	Hold	1,000	–	–	0.04%	416
2021 Q4	$220K	Buy	+1,000	New	+$194K	0.03%	459
2021 Q3	–	Sell	-1,000	Closed	-$202K	–	510
2021 Q2	$202K	Hold	1,000	–	–	0.03%	485
2021 Q1	$215K	Hold	1,000	–	–	0.03%	468
2020 Q4	$236K	Hold	1,000	–	–	0.04%	427
2020 Q3	$272K	Hold	1,000	–	–	0.05%	351
2020 Q2	$290K	Hold	1,000	–	–	0.05%	335
2020 Q1	$238K	Hold	1,000	–	–	0.05%	342
2019 Q4	$219K	Buy	+1,000	New	+$202K	0.04%	467

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's VRTX Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,000 shares — an estimated $392K sold.

NJ State Employees Deferred Compensation Plan first reported a position in VRTX in Q4 2019 and held it in 23 quarters. The position peaked at $485K in Q1 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 1,000 Vertex Pharmaceuticals shares in Q4 2025, an estimated $392K.
NJ State Employees Deferred Compensation Plan first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 23 quarters.
NJ State Employees Deferred Compensation Plan's Vertex Pharmaceuticals position peaked at $485K in Q1 2025.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.